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T of human marrow cells, but not mature peripheral blood cells. It is also found on virtually all unipotent and multipotent colony-forming cells, on blast colony-forming cells, and on precursors of colony-forming cells detectable in long-term marrow culture.'" This antigen has been identified by antibodies MY-10, BI-3C5, ICH3, and 12-8.1-5 The antibody 12-8 was also found to recognize a similar population of marrow cells in nonhuman primates including baboons and macaque species.6 Previous work from our laboratories has demonstrated that isolated autologous CD34+ marrow cells can engraft lethally irradiated baboon~. ' . ~ We and others have observed that the CD34 antigen is not detected on tumor cells from patients with most solid tumors including breast cancer and neuroblast~ma??~ In vitro studies have demonstrated that immunoadsorption with antibody 12-8 can be used to separate normal marrow progenitors from tumor cells.'o In the present study, we asked if populations of enriched CD34+ cells isolated from the marrows of patients with metastatic breast cancer or neuroblastoma were capable of reconstituting hematopoiesis in vivo.
MATERIALS AND METHODS
Antibodies and immunofluorescence staining reagent. The production and characterization of the anti-CD34 antibody 12-8 has been described previously.* This murine IgM antibody was partially purified from ascites fluid using boric acid precipitation.' The biotin conjugate of affinity-purified goat anti-mouse IgM antisera was obtained from Southern Biotechnology Associates (Birmingham, AL). The fluorescein isothiocyanate conjugate of avidin (avidin-FITC) was obtained from Vector Laboratories (Burlingame, CA). The fluorescein isothiocyanate conjugate of goat anti-mouse IgM antisera (GAM-FITC) was obtained from Tag0 (Burlingame, CA).
Avidin obtained from International Enzymes, Falbrook, CA was conjugated to Biogel P-30 (Bio-Rad Laboratories, Richmond, CA) using a previously described p r~c e d u r e .~~"~'~ Each mL of gel contained 100 Fg of avidin.
Nucleated marrow cells (100 x 106/mL) obtained from a buf€y coat preparation were incubated with antibody 12-8 (50 pgimL) in phosphate-buffered saline with 1% bovine serum albumin (PBSDSA) for 30 minutes at 4°C. The cells were washed twice and then incubated at the same cell concentration in PBSIBSA with 0.5 &mL of biotinylated goat anti-mouse IgM antisera for an additional 30 minutes at 4°C. The cells were again washed twice and adjusted to a concentration of 100 X lo6 cells1mL in PBS with 5% BSA for column treatment.
Antibody-treated cells were passed successively through a blood component recipient set (Fenwall Laboratories, Deerfield, IL) and Pharmacia K50130FF column (Pharmacia, Piscataway, NJ) containing carboxylated Biogel P-30 gel (without avidin) to remove debris and cell aggregates. The cells were then passed directly over Chromaflex 15 x 2.5 cm columns (Kontes, Vineland, NJ) containing 20 mL avidin-Biogel at a flow rate of 5.5 mllminute using an Ismatec RegIo 100 pump (Cole-Parmer, Chicago, IL) until the cells had passed through the column (approximately 100 mL volume). Marrows containing greater than 10" cells were divided in half and passed simultaneously over two Kontes columns each containing 20 mL avidin-Biogel. Approximately 100 mL of PBS was then passed through the avidin-Biogel at the same flow rate to wash out BSA. The adherent cells were dislodged by mechanical agitation with a 10 mL pipette until a total volume of 200 mL had been collected.
The washed adherent cells were resuspended to a final volume of 20 mL in a mixture of 16 mL of autologous plasma previously irradiated with
Column treatment.
Cryopreservation, reconstitution, and infusion of cells.
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30.0 Cy from a cesium source and 4 mL of medium 199 with Hanks' salts and L-glutamine (TC199; GIBCO, Grand Island, NY). For cryopreservation, the cell mixture was placed into a DF200 Gambro Hemofreeze bag (Gambro, Dialysatoren, Germany), previously transversely heat-sealed 2 inches from the top of the bag and then rapidly mixed with an equal volume of a 20% DMSO solution in TC199 previously precooled in ice, to provide a final bag volume of 40 mL. For freezing, the Gambro bag was sealed, clamped between precooled copper plates, placed in a controlled rate freezer previously precooled to approximately 2°C as previously described" and cooled at 2 to 2.5"Cimin to -60°C. The cells were then removed from the freezer and placed for storage in the gas phase of liquid nitrogen at -135°C.
For reconstitution the bag was removed from the freezer and rapidly thawed in a water bath at 40°C with constant agitation. Eight milliliters of acid-citrate-dextrose (ACD-A) solution was then added to the bag through the infusion port, gently mixed, and the cells rapidly infused intravenously through a central Hickman line using an intravenous administration set without a filter (2C0001s Soh set; Fenwall, Round Lake, IL).
The Two-stage LTMCs were performed using a modification of previously described metho d~.~~'~. '~ Briefly, 4 x lo6 marrow mononuclear cells were established in 2 mL cultures in McCoy's 5a modified medium (GIBCO) supplemented with sodium pyruvate, essential and nonessential amino acids, vitamins, L-glutamine, sodium bicarbonate, penicillin, Immunofluorescence studies.
Long-term marrow culture (LTMC).
streptomycin, Fungizone, 12.5% horse serum, 12.5% fetal calf serum, and mol/L hydrocortisone succinate. The cell suspension was placed into Lux tissue culture ambitubes (Miles Scientific, Naperville, IL) and incubated at 33°C in a 5% CO, atmosphere. Cultures were maintained by weekly demidepopulation with the addition of fresh medium. Under these conditions a uniform adherent stromal layer developed within 3 to 4 weeks. The primary culture was then irradiated with 10 Cy of y irradiation using a Cesium source. Between 0.09 and 0.7 X lo6 test cells were overlayered on to irradiated allogeneic adherent stromal layers in LTMC. One ambitube from the allogeneic cultures was analyzed weekly. The adherent stromal layers were detached using Type 1 collagenase (240 units/mL, Sigma Chemical Company, St Louis, MO) and granulocyte-macrophage progenitor (CFU-GM) assays were performed in semisolid agar on supernatant and adherent layers separately using placental conditioned medium as a source of colony stimulating a~tivity.",'~ All patients or their legal guardians gave informed consent for treatment on protocols that had been approved by the Institutional Review Board where they received treatment. Patients eligible for transplantation with autologous CD34' enriched marrow cells included individuals with stage IV breast carcinoma, with bone or marrow involvement, whose disease was unresponsive to conventional chemotherapy and/or hormonal therapy, and patients with stage IV neuroblastoma with a history of marrow involvement.
Patients.

RESULTS
Nine patients were treated with myeloablative therapy and then given autologous CD34' marrow cells. The patients' prior history and therapy are summarized in Table l. Table 2 summarizes data from the marrow treatment for the nine patients. A total of 2.5 to 17.5 x 10' nucleated marrow cells were placed on the column, 0.7% to 4.0% of which were CD34'. We recovered 50 to 260 x lo6 adsorbed cells from the columns that were 35% to 92% CD34'. The mean recovery of CD34+ cells was 42 f 13% (range 25% to 58%) in the adsorbed cell fractions (n = 7). The adsorbed cell fractions were highly enriched for precursors of colony-forming cells that grow in LTMC (Table 2) . Isolated CD34' cells from each patient that were cultured over irradiated marrow stroma formed Marrow treutment. For substantial numbers of colonies. In contrast, the unadsorbed cells formed few colonies in LTMC. Two patients with breast cancer were treated with cyclophosphamide, 60 mgkg daily for 2 days, followed by 8 Gy total body irradiation given at a dose rate of 40 cGy per minute by a linear accelerator (Table 3) . Four patients with breast cancer had a history of irradiation and received busulfan, 16 mgkg in 16 doses over 4 days followed by cyclophosphamide, 60 mglkg daily for 2 days.
One breast cancer patient received mitoxantrone, 50 mg/m2 for 1 day, and N,N',N"-Triethylenethiophosphoramide (Thiotepa), 300 mg/m2 daily for 3 days. One patient with neuroblastoma was conditioned with single doses of carmustine (BCNU), 300 mg/m2 and melphalan, 200 mg/m2 in addition to vincristine, 1 mg/m2 for 1 day followed by 0.5 mg/m2 daily for 3 additional days. A second patient with neuroblastoma received cyclophosphamide 60 mgkg daily for 2 days, L-phenylalanine mustard, 220 mg/m2, and fractionated total body irradiation, 200 cGy per day for 6 days.
Engraftment. Following conditioning, patients received 1.0 to 5.2 X lo6 CD34-enriched cellskg (Table 3) . Six patients survived more than 17 days and achieved trilineage engraftment as documented by marrow examination as well as recovery of peripheral blood counts. The days to reach a granulocyte count over 500/mm3 ranged from 21 to 47 days (mean, 34 * 10 days), while the time to recovery of platelets to greater than 20,000/mm3 was 28 to 66 days (mean, 46 f 14 days). All six patients became independent of erythrocyte and platelet transfusions. Follow-up studies in all of these patients except patient 8 (see below) performed 30 to 60 days posttransplant demonstrated normocellular marrow with the presence of all lineages. Subsequently, five patients died but had normocellular marrow at autopsy and normal peripheral blood counts at the time of dcath.
Conditioning regimen.
Patient 8 had a granulocyte count of 220/mm3 at day 35. He was started the following day on a 10-day course of recombinant human GM-CSF (250 pg/m2/d). However, his granulocyte count rose and remained over 500/mm3 by day 37 where it remained and he became independent of platelet transfusions by day 66. He relapsed shortly thereafter and his bone marrow showed massive infiltration of neuroblastoma cells concomitant with a renewed requirement for platelet transfusions. Three patients died at days 17,14, and 14 posttransplant, two of infections and one of pulmonary hemorrhage. Two of these patients had rising granulocytes counts at the time of death. Additionally, marrow examinations performed at day 14 in these two patients showed evidence of bilineage or trilineage engraftment with 20% and 40% of normocellularity, respectively. A marrow sample was not obtained on the third patient. 
DISCUSSION
We have now shown that marrow preparations highly enriched for CD34' cells obtained from patients with metastatic breast cancer or neuroblastoma are capable of reconstituting hematopoiesis in vivo after myeloablative therapy. Evidence that the radiation treatment regimens used in this study (patients 1, 2, and 8) were myeloablative comes from extensive experience in and in hum a n~'~. *~ that has demonstrated that total body irradiation exposures of 6 Gy and greater are myeloablative even at dose rates slower than those described in this study. Previous work in rats and clinical experience in humans suggest that the busulfan and cyclophosphamide regimen used for patient 3, 5, 6, and 7 was also myeloablative.2'~" Data supporting the myeloablative properties of the chemotherapy regimen used in patient 4 are less definitive, although clinical studies have demonstrated that patients treated with melphalan at doses greater than 140 mg/m* require bone marrow r e i n f u s i~n .~~'~~ Clinical trials have shown that patients receiving Thiotepa at total doses in excess of 180 mg/m' require marrow transplant for hematologic recovery." Furthermore, mitoxantrone doses greater than 30 mgim' have not been given to patients without a subsequent marrow transplant, because of severe and prolonged myelo-suppres~ion.~~~~~ Therefore, it is probable that the high dose combination of Thiotepa and mitoxantrone given to patient 9 also had marrow ablative properties.
The rate of engraftment of patients 3,4, and 9 was similar to that seen in patients receiving unmodified autologous marrow. However, patients 1, 2, and 8 showed delayed hematologic recovery. Possible explanations for this delay include adverse effects of the immunoadsorption procedure, cryopreservation damage of purified hematopoietic progenitors, or injury to hematopoietic progenitors caused For personal use only. on October 22, 2017. by guest www.bloodjournal.org From by previous chemotherapy given to these patients. In patient 8, the presence of occult neuroblastoma in the marrow before frank relapse may have contributed to poor marrow function. Indeed, poor initial engraftment has been observed in patients undergoing autologous marrow transplantation who later relapsed." Studies of larger numbers of patients are needed to determine the factors that may influence rate of hematologic recovery in patients receiving CD34+ cells.
Although we saw no clear adverse effects of positive stem cell selection, it may have contributed to delay of engraftment in some patients. It is unknown whether immunologic reconstitution occurred in these patients. Two patients with metastatic breast cancer treated with total body irradiation died of idiopathic interstitial pneumonitis (IIP). IIP has also been observed in patients with breast cancer who received unmodified autologous marrow after conditioning with an identical chemoradiotherapy regimen and was felt to be secondary to the high radiation dose rate (40 cGy/min) (C. Collins, personal communication). Consequently, it is unlikely that the infusion of CD34' cells contributed to the development of IIP in these two patients. Patient 3 died of aspergillosis at day 306 while on dexamethasone for an undiagnosed neurologic syndrome but had normal peripheral blood counts, marrow examination, and no evidence of recurrent disease at autopsy.
These studies provide evidence that CD34' human marrow cells can reconstitute in vivo hematopoiesis after marrow ablative therapy. Conclusive proof that they account for long-term hematopoiesis await studies in which the infused cells can be distinguished from recipient cells that may have survived the myeloablative treatment. Additionally, it is possible that contaminating non-CD34' cells that were also infused may have played a role in engraftment. Work is in progress to improve the selectivity of CD34' cells using the avidin-biotin immunoadsorption procedure.
Although the selection of stem cells may provide a generic approach to obtain engrafting hematopoietic cells, the efficacy of tumor cell depletion using this positive selection technique remains to be determined. Furthermore, the high relapse rates observed in patients receiving allogeneic transplants suggest that current conditioning regimens may not eradicate residual tumor in patients. Until more effective conditioning regimens have been developed, the contribution of residual tumor cells in infused marrow to relapse after autologous marrow transplantation will remain unclear. The clinical role of positive stem cell selection in autologous marrow transplantation therefore will require further study.
